Design And Production Of Anti Erbb2-Toxin As A Novel Anticancer Candidate Of Breast Cancer

Breast cancer remains the leading cause of cancer death in females. In spite of advancedimprovement in clinical medicine, primary and secondary resistance is encountered worldwide.Over expression of human epidermal growth factor 2 receptor occurs in approximately 30% ofpeople with breast cancers. Due to poor patient prognosis, immunotoxins have been suggested andused as an efficient therapeutic agent. Immunotoxins are chimeric proteins contain of a specificcellular targeting domain linked to a cytotoxic factor. In this study, we introduces a novelrecombinant immunotoxin-based protein to enhance efficacy of targeting specific cancer cellsthrough conjugating effective toxin to HER2 ligand. In order to produce a recombinant anti Erbb2-toxin consisting of insect toxin with high affinity for HER2/neu receptor, we have used an expressionmatrix including two expression vectors including pET and Cold Shock expression System, threedifferent E. coli hosts; BL21 (DE3), Rosetta-gami plysS and T7 shuffle B and five solubilizationconditions containing 6 different buffers with various organic components in different pH. Ouranticancer agent has demonstrated high level of protein expression when produced in Cold Shockexpression System (BL21) compared to pET expression system. In addition, the best solubilizationbuffer contains triton x-100. Anti Erbb2-toxin can be a potential candidate with remarkableproficiency for treating breast cancer patients having high expression levels of Her2 receptor. Thegenerated soluble recombinant immunotoxin is a good candidate for breast cancer therapy.